Blue Trust Inc. Has $229,000 Position in Cencora, Inc. (NYSE:COR)

Blue Trust Inc. decreased its stake in Cencora, Inc. (NYSE:COR - Free Report) by 63.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,021 shares of the company's stock after selling 1,755 shares during the period. Blue Trust Inc.'s holdings in Cencora were worth $229,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Concord Wealth Partners purchased a new position in Cencora in the third quarter valued at about $30,000. Householder Group Estate & Retirement Specialist LLC boosted its holdings in Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after purchasing an additional 69 shares during the last quarter. Kentucky Trust Co purchased a new position in Cencora in the fourth quarter valued at about $33,000. Ashton Thomas Securities LLC purchased a new position in Cencora in the third quarter valued at about $41,000. Finally, Modus Advisors LLC purchased a new position in Cencora in the fourth quarter valued at about $54,000. Hedge funds and other institutional investors own 97.52% of the company's stock.

Cencora Price Performance

NYSE COR traded down $1.99 on Friday, reaching $241.47. 1,060,827 shares of the stock traded hands, compared to its average volume of 1,564,268. The firm's fifty day simple moving average is $239.52 and its 200 day simple moving average is $237.46. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The company has a market cap of $46.83 billion, a price-to-earnings ratio of 34.35, a P/E/G ratio of 1.31 and a beta of 0.49. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $262.26.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, research analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be issued a $0.55 dividend. The ex-dividend date is Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.91%. Cencora's payout ratio is currently 31.29%.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on COR. UBS Group upped their price objective on Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Evercore ISI upped their price objective on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Barclays upped their price objective on Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Robert W. Baird increased their price target on Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a research report on Thursday, November 7th. Finally, Wells Fargo & Company increased their price target on Cencora from $237.00 to $251.00 and gave the stock an "equal weight" rating in a research report on Wednesday, January 29th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, Cencora has a consensus rating of "Moderate Buy" and an average target price of $277.90.

Insider Activity

In related news, EVP Silvana Battaglia sold 1,678 shares of the business's stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now owns 20,329 shares of the company's stock, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Chairman Steven H. Collis sold 50,000 shares of the business's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the completion of the sale, the chairman now directly owns 326,557 shares of the company's stock, valued at approximately $79,670,111.29. The trade was a 13.28 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 10.80% of the company's stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.